Risedronate (Na)

Drug #1491

Risedronate (Na) is a bisphosphate with similar properties to those of bisphosphonates in general. It inhibits bone resorption and is used in Paget`s diseaseof bone and in the treatment of post-menopausal osteoporosis to redce risk of vertebral or hip fractures.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin.

Molecular Weight: 305.1 · Non-proprietary name: Risedronate (Na).

Pharmacokinetics

Elimination: renal excretion is 50 % unchanged.

Indications

Risedronate (Na) is primarily indicated in conditions like Pagets disease, Paget's disease of bone, Postmenopausal osteoporosis.

Contraindications

None recorded.

Dosage

Risedronate (Na)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
5 mg	5 mg	Every 24h	PO	For treatment and prevention of Postmenopausal Osteoporosis:
5 mg	5 mg	Every 24h	PO	Treatment and Prevention of Glucocorticoid-Induced Osteoporosis:
30 mg	30 mg	Every 24h	PO	Treatment of Paget''s Disease :Retreatment may be considered (following post-treatment observation of at least 2 months) if relapse occurs, or if treatment fails to normalize serum alkaline phosphatase.
35 mg	35 mg	—	PO	Treatment to Increase Bone Mass in Men with Osteoporosis: Taken once a week.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

4 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Risedronate (Na) is known to cause more or less tolerable side effects which are usually transient. These include Abdominal pain, Constipation , Diarrhea, Nausea and vomiting.

Warnings / Precautions

Hypocalcemia should be corrected before beginning therapy. Tablets should be taken on rising for the day, on an empty stomach, atleast 30 minutes before breakfast and other oral drug. To minimize the gastro-intestinal effects of the drug patients should be instructed to swallow tablety with plenty of water in an upright position (standing or sitting). Patient should remain upright after taking the tablet and should not lie down for at least 30 minutes.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Tabs

150 mg 35 mg 5 mg

Storage Conditions

Risedronate (Na) should be stored .

Drug Classification

1.18.14 — Drugs affecting bone metabolism

Manufacturers

Manufacturers of Risedronate (Na) in Pakistan:

Akson Atco Aventis Bosch Candid CCL Genix Gray's Hansel Hilton Martin Pharmix Rotex S.J.& G Scotmann Shaigan Swan TG Wilshire